What 400+ Medtech Founder Interviews Reveal About B2B Demand Generation Agency Limits

A B2B demand generation agency builds pipeline for markets that already understand the problem they solve. Most pre-traction medtech companies don't have that market yet, so the pipeline the agency builds never converts.

The remedy isn't better targeting or more content. It's engineering the category first, then handing a demand generation agency a market that's ready to respond.

I covered this on a recent episode about why medtech founders raise capital without traction: How Market Engineering Helps MedTech Startups Raise Capital.

Key Takeaways

• A B2B demand generation agency assumes the market already exists. Most pre-traction medtech companies haven't built one yet.
• Bruce Cleveland's research shows 85% of B2B startups fail, and the leading cause is market-product fit, not product quality.
• Demand generation optimizes for pipeline volume. Market engineering builds the category that makes the pipeline convert.
• FDA clearance and clinical validation don't create demand on their own. Validation is not translation.
• The answer isn't skipping demand generation. It's sequencing market engineering before it.

‍

Why a B2B Demand Generation Agency Cannot Fix a Market That Has Not Formed

Most demand generation agencies run the same playbook regardless of industry. Define the ICP, build the funnel, run the campaigns, measure the pipeline.

That playbook works when buyers already recognize the category. It breaks the moment they don't.

I covered this on the episode about raising capital without traction:

"Don't confuse attention with demand. Demand has to be sustained after launch. You can't outsell a misdefined market. All right, you just can't do it."

Medtech founders hire a B2B demand generation agency expecting pipeline. What they get instead is a lot of attention and very little conversion. So the agency gets blamed for a problem it was never equipped to solve.

The market wasn't ready to receive the message. No amount of campaign optimization changes that.

This is the pattern I see most often when a board pushes for pipeline before the category is settled. The demand generation agency delivers exactly what it was hired to deliver: impressions, clicks, and a lead list.

What it can't deliver is a market that already understands why the product matters, because that work was never done upstream.

So the founder ends up paying twice. Once for the campaigns that didn't convert, and again for the category work that has to happen anyway before the next round of campaigns can land.

What Bruce Cleveland's Research Shows About Why B2B Startups Fail Before Demand Generation Even Starts

Bruce Cleveland spent years studying why venture-backed companies fail after they've already built something real. His research points at the same root cause I've watched play out across 400+ episodes of State of MedTech.

I interviewed Bruce Cleveland, creator of the Traction Gap framework, on an episode about product-market fit and category design. He said:

"85% Of most startups fail B2B, 96% of B2C fail. They fail because they don't do market-product fit work very well. They fail to create a category, a differentiated category."

It's a category problem, and a demand generation agency can run flawless campaigns against a category that doesn't exist yet while the numbers still refuse to move.

Founders read the failure as a marketing execution issue. So they hire another agency, run another campaign, and get the same result.

Why Clinical Validation Does Not Create the Demand a B2B Demand Generation Agency Needs to Convert

Medtech founders have an advantage most B2B categories don't: FDA clearance, clinical data, physician champions who love the device. And yet procurement won't move.

I explained why on the same episode:

"Validation is not translation. Just because you have clinical proof that it works doesn't mean that you're going to have adoption. If users don't understand when to use it or why they would use it, that's a market failure."

A B2B demand generation agency can put that clinical proof in front of the right buyer a hundred times. But if the buyer doesn't understand where the product fits in their workflow, the proof doesn't translate into a decision.

That's a market engineering problem. It has to be solved before pipeline volume means anything.

I've had well-capitalized companies come to us after a few years of commercial activity and ask why they aren't getting traction. When I look at what they've built, the answer is usually the same: some of the basic category work was never done.

Hiring more sales reps or running more campaigns through a demand generation agency doesn't fix that. You can't outsell a market that was never defined.

What Happens When Founders Improvise the Category a B2B Demand Generation Agency Needs

Medtech founders apply real discipline to product development. Clinical trials, regulatory submissions, and engineering sign-off all follow a structured process with clear gates.

Category definition rarely gets the same treatment. I described this gap on the same episode about raising capital:

"What ends up happening is that companies go from structured product engineering to improvising everything about the category, about the narrative, about the messaging. That's where a lot of these things break."

A B2B demand generation agency inherits whatever category work exists at the moment it's hired. When that work was improvised, the agency improvises too, testing messaging angles in live campaigns instead of executing against something already validated.

That's an expensive way to find out what the category should have been. Every campaign becomes market research paid for at ad rates instead of strategy rates.

Founders who invest the same rigor in category design that they apply to product development give their eventual demand generation agency something solid to execute against. The campaigns still take testing and iteration, but they're refining a defined message, not discovering one from scratch.

How Medtech Founders Should Sequence a B2B Demand Generation Agency After Market Engineering, Not Before

The remedy isn't avoiding demand generation. Cleared, well-funded medtech companies eventually need pipeline at scale, and a good demand generation agency is genuinely useful once the category exists.

The sequence matters more than the tactic. Category design and market-product fit come first. Messaging and narrative come next. Demand generation comes last, once there's a defined market to generate demand inside of.

I've watched founders skip straight to the last step because it feels like progress. Campaigns launch, dashboards fill up, and it looks like momentum. But pipeline without a defined category is a leaky bucket, not a growth engine.

Founders who reverse the order, category first, then demand generation, see the difference immediately. The same campaign spend converts because the market can finally recognize what it's looking at.

The metrics change in a specific way. Cost per lead often stays flat, but the leads that come in are further along, because the campaign is reinforcing something the buyer already half-believes rather than introducing a new idea from zero. Sales cycles shorten because reps spend less time educating and more time closing.

This connects directly to what I've written about building a healthcare content marketing engine that engineers demand instead of capturing it, content and demand generation are downstream of the same category work.

What This Means for Medtech Founders

In my experience working with medtech founders, the demand generation agency conversation almost always comes too early. Founders want pipeline because pipeline is measurable, and category design feels abstract by comparison.

But category design is the more urgent work. Every dollar spent on demand generation before the category is defined is a dollar spent building pipeline that won't convert.

I tell founders to ask one question before signing any demand generation contract: can a buyer explain, in their own words, why this category exists and why it matters to them right now? If the answer is no, the market hasn't formed yet.

Once it has, a demand generation agency becomes one of the best investments a commercial medtech company can make. Before that point, it's the wrong tool for the problem.

This isn't an argument against demand generation as a discipline. It's an argument about sequence. The agencies that produce real pipeline for medtech clients are usually working with a company that already knows what category it owns, and the campaigns simply amplify a message the market is ready to hear.

The founders who skip that step aren't lacking urgency. They're usually under real pressure from a board or an investor to show pipeline activity, and a demand generation contract looks like progress on a slide.

But activity isn't traction, and a dashboard full of impressions doesn't answer the question a buyer is asking, which is why this category matters to them right now.

Frequently Asked Questions

What does a B2B demand generation agency do for a medtech company?

A B2B demand generation agency builds and runs campaigns designed to generate pipeline: paid media, content syndication, email sequences, and lead scoring. It assumes the target buyer already recognizes the problem and the category solving it, and optimizes conversion from there.

Why does demand generation fail for pre-traction medtech startups specifically?

Pre-traction medtech startups haven't defined the category their buyers should place them in. Demand generation campaigns convert attention into pipeline, but only when the market already understands what it's looking at. Without that, campaigns generate impressions without conversions.

What should a medtech founder do before hiring a demand generation agency?

Define the category, the market-product fit, and the narrative first. This is market engineering work: naming the problem the way the ICP already recognizes it, then building messaging around that definition. Demand generation should come after that work is done.

How long does market engineering take before a B2B demand generation agency should get involved?

There's no fixed timeline, since it depends on how far off the current category definition is from the market's actual understanding. Founders working from a clear category can move to demand generation in weeks.

Founders redefining an entire category against an incumbent standard need longer, since messaging and narrative both need to hold up under real buyer scrutiny before campaigns amplify them.

Listen to the Full Conversations

I covered the market engineering framework on How Market Engineering Helps MedTech Startups Raise Capital. Bruce Cleveland joined me on The Truth About Product-Market Fit, Category Design & Why Startups Waste Funding. Subscribe wherever you listen to podcasts.

About the Author

Omar Khateeb is the founder of MarketCraft and host of The State of MedTech, one of the leading podcasts in the medtech industry.

He works with medtech founders and commercial leaders on market engineering, commercialisation strategy, and revenue growth. Visit marketcraft.ai or subscribe to The State of MedTech for weekly conversations with the people building the future of medical devices.